Board of Directors


Jon Moulton
Non-Executive Chairman

Jon has been an institutional and personal investor in numerous biotech and pharma companies over the past 30 years. He established Schroder Life Sciences and was the initial external investor in Shire.

He is now Chairman of several companies including FinnCap, the leading AIM broker, a trustee of the UK Stem Cell Foundation and is also the primary funder of an active clinical trials charity.

Dr Peter Jackson
Executive Director

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.

Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director then VP of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

During 2015-16, Dr Jackson was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.

Dr Tony Flinn
Non-Executive Director

An entrepreneur and general business manager with competence in research, development, applied technology, sales, marketing, new business development, finance, business planning, business funding and general management.

Originally a scientist with a degree and PhD in chemistry, Tony started in research then moved to development and technical management roles. In 2000 he founded Onyx Scientific Ltd and as CEO with major business development responsibilities grew the business successfully. The company won the NE Small Business of the Year award and was cited as a top 20 fastest growing technology company in the UK. In 2007 Tony managed an MBO and in 2011, a trade sale. Tony has subsequently been involved in several successful life science and consumer businesses and currently operates as a business coach, mentor and advisor, motivational speaker, non-exec director and management consultant.

Dr Chris Doherty
Non-Executive Director

A graduate pharmacist later completing a PhD, a Post-Doctoral Fellowship in pharmaceutical technology and then an MBA, Chris has worked at three large pharma companies over 26 years: Glaxo in Canada/UK in development and production roles; Roche as Head of Pharmacy R&D for the UK; and then AstraZeneca in 1997 to lead an international pharmaceutical sciences group. This was followed by broader experience running R&D/commercial/clinical teams for late phase development projects in oncology as well as a site leadership role at Alderley Park.

Chris is currently Managing Director, Alderley Park for the site’s owners Bruntwood, with responsibility for the science park, C-Level company engagement and investment fund aspects. There are 58 established companies at the site and circa 94 companies have been incorporated there, many working through the pre-start incubation programme. All are in the Biotech sector or associated with it including a number in the AMR field.

Dr Hakim Yadi OBE
Non-Executive Director

Hakim is CEO of the Northern Health Science Alliance Ltd (NHSA). He led the formation of the NHSA, bringing together 20 NHSA members as a single health partnership across the North of England.

Previously he was at PA Consulting Group where on secondment to UK Government he was Chief Operations Officer and founding member of the Department Of International Trade Life Sciences Organisation.

Hakim holds a PhD in the Immunology of Pregnancy from the University of Cambridge. He was awarded an OBE in the 2017 New Year’s Honours list for services to healthcare technology and the economy.

Management


Dr Peter Jackson
Executive Director

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past ten years, he has created six new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services.

Dr Jackson has over 25 years’ experience in the sector, previously holding senior executive roles as commercial director then VP of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

During 2015-16, Dr Jackson was chairman of the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, and now runs the enterprise as its executive director.

Ian Grundy
Chief Business Officer

“What a fantastic opportunity we have with the AMR Centre, to face head on this major threat to world health. We can’t and won’t fail.” – Ian Grundy

Ian Grundy is an experienced international business development professional, with over 20 years pharmaceutical and technology licensing experience. Before joining the AMR Centre he was Global head of Sales and Marketing at Ajinomoto-OmniChem and also sat on the board of their Indian joint venture, GOC.

Prior to that Ian held senior commercial/licensing positions within TeraView, a Cambridge based technology start-up, Piramal Healthcare, Avecia and Zeneca.

Dr Derek Lindsay
Chief Operating Officer

Derek was a co-founder of Redx Pharma and its Chief Operating Officer from 2012-17. His former roles include being a Director of Innovation of pharmaceutical industry consortium Britest Ltd from 2006 to 2012, and R&D Director of Avecia Pharmaceutical Products in a management career of more than 20 years. Derek has worked in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985.

Dawn Watson
Chief Financial Officer

Experienced Financial Director of both high potential start-ups and established businesses across a broad range of industries. Having trained with Ernst & Young and after gaining many years in industry established her own company in 2010, FinStra Ltd, to provide strategic and financial support either as a part time or ad hoc Finance Director together with undertaking specific projects to help companies achieve their full potential.

Scientific & Technical Advisory Board


Prof. Ian Greer

S&TAB Chairman

Chairman of the NHSA, Vice President of the University of Manchester and Dean of its faculty of Medical and Human Sciences

Prof. William Hope

University of Liverpool (Clinician-scientist; PK-PD modelling; pre-clinical development; anti-fungal drug discovery

Prof. Jeff Errington

Newcastle University (Microbiology; small-molecule antibacterial discovery research; natural product discovery; bacterial cell biology; founder of Prolysis Ltd and Demuris Ltd)

Prof. David Livermore

University of East Anglia (Medical microbiology; antibiotic resistance mechanisms, particularly beta-lactamases; epidemiology)

Dr Nell Moore

Vice President, Clinical Development AstraZeneca Antibiotics

Dr David Cook

Chief Scientific Officer, Blueberry Therapeutics